Navigation Links
Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
Date:3/12/2008

VIENNA, Austria, March 12 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it will open a research facility in Cambridge, UK in addition to its headquarters in Vienna, Austria. The facility will be located at the Babraham Research Campus, home to a number of biotech companies and close to the Medical Research Council's Laboratory of Molecular Biology (LMB), the major center for antibody engineering in Europe.

The research site will start operations on April 15, 2008. The group located in Cambridge will mainly be responsible for lead generation based on the company's Modular Antibody Technology as well as, in the future, for research related to the conduct of collaborative studies between f-star and its pharma and biotech partners.

f-star's Cambridge site will start with a small group of highly experienced researchers in the field. The research group will be headed by Lutz Riechmann, a senior researcher with over 20 years of experience in antibody research in Sir Gregory Winter's group at the LMB.

"We are excited to open up a lab at the epicenter of Europe's antibody research and development community and to utilize the large pool of talent and experience concentrated in the Cambridge area," says Gottfried Himmler, CEO.

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAb2) can be created.

f-star was founded by a team of experienced antibody engineering and biotech executives in 2006. Seed-financed by Austrian government agencies and Atlas Venture, the company recently closed a Series A financing round with Aescap Venture, Atlas Venture and Novo A/S and has raised EUR 13.0m in total so far. In its advisory board, the company is supported by pioneers in the field of monoclonal antibodies. f-star has 18 employees at its headquarters in Vienna, Austria and recently opened a second research site in Cambridge, UK.
For more information, visit http://www.f-star.com

Company contact:

Dr. Eugen Stermetz

CFO

f-star Biotechnologische Forschungs- und Entwicklungs-GmbH

+43-72055-4215

Gastgebgasse 5-13

A-1230 Vienna, Austria

office@f-star.com

Media contact:

Frank Butschbacher

Investor Relations & Communications

+43-650-78 44 940

office@butschbacher.net

http://www.butschbacher.net


'/>"/>
SOURCE f-star
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
2. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
3. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
4. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
5. Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer
6. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
7. Abbott Scientists Create One Molecule With Two Antibody Functions
8. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
9. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
10. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
(Date:10/9/2017)... , ... October 09, 2017 ... ... on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® ... gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface ...
(Date:10/7/2017)... , Oct. 6, 2017  The 2017 Nobel ... three scientists, Jacques Dubochet, Joachim Frank ... in cryo-electron microscopy (cryo-EM) have helped ... the structural biology community. The winners worked with ... now routinely produce highly resolved, three-dimensional images of ...
Breaking Biology Technology:
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):